Drug action, reaction, and interaction. II. Iatrogenic cardiopathies.
D000777:Anesthetics / Q000009:adverse effects; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001463:Barbiturates / Q000009:adverse effects; D001949:Bretylium Compounds / Q000009:adverse effects; D001993:Bronchodilator Agents / Q000009:adverse effects; D002800:Cholinesterase Inhibitors / Q000009:adverse effects; D004071:Digitalis Glycosides / Q000009:adverse effects; D004232:Diuretics / Q000009:adverse effects; D004347:Drug Interactions; D006331:Heart Diseases / Q000139:chemically induced*; D006728:Hormones / Q000009:adverse effects; D006801:Humans; D007049:Iatrogenic Disease; D008012:Lidocaine / Q000009:adverse effects; D009203:Myocardial Infarction / Q000139:chemically induced; D010277:Parasympathomimetics / Q000009:adverse effects; D010672:Phenytoin / Q000009:adverse effects; D011342:Procainamide / Q000009:adverse effects; D011433:Propranolol / Q000009:adverse effects; D011802:Quinidine / Q000009:adverse effects; D019966:Substance-Related Disorders / Q000150:complications; D013566:Sympathomimetics / Q000009:adverse effects; D014662:Vasoconstrictor Agents / Q000009:adverse effects
D000777:Anesthetics; D000929:Antidepressive Agents, Tricyclic; D000959:Antihypertensive Agents; D001463:Barbiturates; D001949:Bretylium Compounds; D001993:Bronchodilator Agents; D002800:Cholinesterase Inhibitors; D004071:Digitalis Glycosides; D004232:Diuretics; D006728:Hormones; D010277:Parasympathomimetics; D013566:Sympathomimetics; D014662:Vasoconstrictor Agents; D010672:Phenytoin; D008012:Lidocaine; D011433:Propranolol; D011802:Quinidine; D011342:Procainamide